Table 1.
Population and study sample characteristics
| All Atypical Antipsychotic Users (n = 7,141) | Study Sample (n = 830) | |||
|---|---|---|---|---|
| Variable | Count | (%) | Count | (%) |
| Age, mean (SD) | 42.0 | (11.2) | 43.3 | (11.5) |
| Female | 3,796 | (53.2%) | 527 | (63.5%) |
| Race | ||||
| White | 6,341 | (88.8%) | 725 | (87.3%) |
| Native American | 220 | (3.1%) | 34 | (4.1%) |
| African-American | 263 | (3.7%) | 27 | (3.3%) |
| Hispanic | 164 | (2.3%) | 23 | (2.8%) |
| Asian | 104 | (1.5%) | 15 | (1.8%) |
| Other/unknown | 49 | (0.7%) | 6 | (0.7%) |
| Medicare Dual Eligible | 2,792 | (39.1%) | 290 | (34.9%) |
| Urban residence | 5,379 | (75.3%) | 614 | (74.0%) |
| Diagnoses | ||||
| Depression | 2,075 | (29.1%) | 430 | (51.8%) |
| Anxiety | 1,394 | (19.5%) | 281 | (33.9%) |
| Bipolar Disorder | 1,558 | (21.8%) | 222 | (26.7%) |
| Schizophrenia | 2,236 | (31.3%) | 121 | (14.6%) |
| Dementia | 80 | (1.1%) | 8 | (1.0%) |
| Personality Disorder | 121 | (1.7%) | 17 | (2.0%) |
| Post-Traumatic Stress Disorder | 567 | (7.9%) | 122 | (14.7%) |
| Insomnia | 240 | (3.4%) | 64 | (7.7%) |
| Other Psychiatric Diagnoses | 607 | (8.5%) | 59 | (7.1%) |
| Any of Above Diagnoses | 6,106 | (85.5%) | 736 | (88.7%) |
| Initiating Prescriber | NA | |||
| Psychiatry | 176 | (21.2%) | ||
| General practice | 214 | (25.8%) | ||
| Nurse Practitioner | 94 | (11.3%) | ||
| Other | 45 | (5.4%) | ||
| Unidentified | 301 | (36.3%) | ||
| Drug* | ||||
| Quetiapine | 2,715 | (38.0%) | 335 | (40.4%) |
| Olanzapine | 2,483 | (34.8 %) | 238 | (28.7%) |
| Risperidone | 2,317 | (32.4%) | 208 | (25.1%) |
| Ziprasidone | 592 | (8.3%) | 46 | (5.5%) |
| Clozapine | 352 | (4.9%) | 3 | (0.4%) |
| Subtherapeutic dose | 3,689 | (51.7%) | 348 | (66.0%) |
*
Because patients could have used more than 1 agent, sum does not equal n among All Atypical Antipsychotic Users